Treatment of Acquired Immunodeficiency Syndrome in Pregnancy
Clinical Scenario
This protocol addresses the management of HIV/AIDS in a person who is pregnant. Pregnancy represents a specific clinical context that shapes both the urgency and the choice of antiretroviral therapy.
Immediate initiation of ART is recommended for all individuals with HIV who are pregnant — for reasons of maternal health and to prevent perinatal and sexual transmission.
Treatment Approach (partial overview)
Management centres on immediate antiretroviral therapy. A recommended first-line regimen combines an integrase strand transfer inhibitor with a dual nucleoside/nucleotide backbone selected based on availability — with an alternative combination-tablet regimen also available.
Specific agent selection, dosing, sequencing, and monitoring detail are in the full structured protocol.
References
DOI: 10.1001/jama.2024.24543
Immediate initiation of ART is recommended for all individuals with HIV who are pregnant for reasons of maternal health and to prevent perinatal and sexual transmission (evidence rating: AIa).
Dolutegravir with TAF/FTC (or TDF/XTC if TAF/FTC is not available) is the recommended ART regimen in pregnancy and in persons who plan to become pregnant because of high antiviral efficacy and low rates of adverse birth outcomes (evidence rating: AIa).
BIC/TAF/FTC is an alternative regimen (evidence rating: BIIa).
View source ↗